LOS ANGELES--(BUSINESS WIRE)--May 23, 2006--BARRX Medical, Inc. today announced that nine clinical studies involving the HALO360 and HALO90 Systems were presented at Digestive Disease Week® (DDW®), May 20-25, 2006, in Los Angeles. The studies demonstrate the benefits of the HALO360 and HALO90 Systems for treating Barrett’s esophagus, a precancerous condition caused by chronic acid reflux disease or GERD. Left untreated, Barrett’s esophagus can lead to a dangerous form of cancer called esophageal adenocarcinoma--the fastest rising type of cancer in the United States today.
